BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 35724948)

  • 1. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response and progression on midostaurin in advanced systemic mastocytosis:
    Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
    Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avapritinib for Systemic Mastocytosis.
    Bose P; Verstovsek S
    Expert Rev Hematol; 2021 Aug; 14(8):687-696. PubMed ID: 34289787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
    Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
    Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
    Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
    J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
    Baird JH; Gotlib J
    Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new tool "
    Shomali W; Gotlib J
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH
    Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis.
    Schwaab J; Cabral do O Hartmann N; Naumann N; Jawhar M; Weiß C; Metzgeroth G; Schmid A; Lübke J; Reiter L; Fabarius A; Cross NCP; Sotlar K; Valent P; Kluin-Nelemans HC; Hofmann WK; Horny HP; Panse J; Reiter A
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3121-3127.e1. PubMed ID: 32422371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avapritinib for advanced systemic mastocytosis.
    Gotlib J; Reiter A; DeAngelo DJ
    Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.
    Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
    Valent P; Akin C; Hartmann K; Reiter A; Gotlib J; Sotlar K; Sperr WR; Degenfeld-Schonburg L; Smiljkovic D; Triggiani M; Horny HP; Arock M; Galli SJ; Metcalfe DD
    J Allergy Clin Immunol; 2022 Jun; 149(6):1866-1874. PubMed ID: 35421448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Reiter A; George TI; Gotlib J
    Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
    Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
    Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Pardanani A
    Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
    Gotlib J
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.